Clinical pharmacokinetics profile of ivermectin 1% cream after dermal applications on the face

Table 4 Ivermectin plasma concentrations (ng/mL) obtained after repeated topical applications of ivermectin 1% cream QD in subjects with papulopustular rosacea (maximal use pharmacokinetic trial and phase 3 studies #1, #2)

Treatmentduration	Maximal use PK study1	Study #12	Study #23
Week 2	1.3 ± 0.5 (0.6 to 2.3)	NA	NA
Week 4	1.4 ± 0.6 (0.5 to 3.0)	NA	NA
Week 12	NA	0.5 ± 0.7 (< 0.05 to 6.0)	0.4 ± 0.5 (< 0.05 to 2.8)
Week 32	NA	0.4 ± 0.4 (< 0.05 to 3.1)	0.4 ± 0.5 (< 0.05 to 2.9)
Week 52	NA	0.3 ± 0.4 (< 0.05 to 2.2)	0.4 ± 0.6 (< 0.05 to 3.80)

PK: Pharmacokinetic; NA: Not applicable;

¹N: 14 (week 2), n = 15 (week 4);

²N = 105 (week 12), n = 77 (week 32), n = 73 (week 52);

³N= 92 (week 12), n = 84 (week 32), n = 65 (week 52); Note: Data represent Mean ± SD, and minimum to maximum, as available. BLQ data were imputed to the LOQ of 0.05 ng/mL for the maximal use PK study C_min concentration is displayed. For Study #1 and #2 blood samples were taken approximately 12 h after drug application.